To minimise reactions: ensure proper injection technique, rotate sites consistently, avoid injecting into areas with skin conditions, and never reuse needles
Too short a needle might deliver the solution in the dermis (upper skin layer) instead of subcutaneously, while too long a needle can cause unnecessary tissue damage
Category-wise Analysis By Product, Ozempic Dominates the GLP-1 Receptor Agonist Market Ozempic (semaglutide) dominates with 32.1% share of the global market in 2025 , due to its strong efficacy in both glycemic control and weight management
10.1515/revneuro-2016-0018 55
Clinical trials of Ozempic demonstrate that gastroesophageal reflux disease occurred in 1.9% of patients taking 0.5 mg Ozempic and 1.5% of those taking 1 mg Ozempic compared to 0% with placebo
The FDA's April 2026 announcement to remove injectable GHK-Cu from the Category 2 restricted list is significant here